# Azenta, Inc.: financial statements, quarterly

AZTA · Nasdaq · CIK 933974 · [Industrials](/sectors/industrials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/azta.md) · [Financials](/companies/azta/financials.md) · [Filings](/companies/azta/filings.md) · [Insiders](/companies/azta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/azta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [58.8 d](/filings/0001437749-25-036931.md) | [142](/filings/0001437749-25-036931.md) | [136](/filings/0001437749-25-036931.md) | [144](/filings/0001437749-25-036931.md) | [151](/filings/0001437749-25-036931.md) | [147](/filings/0001437749-26-003200.md) | [143](/filings/0001628280-26-032557.md) | [144](/filings/0001628280-26-054295.md) | [159](/filings/0001437749-25-036931.md) | [149](/filings/0001437749-26-003200.md) | [145](/filings/0001628280-26-032557.md) | [161](/filings/0001628280-26-054295.md) |
| Cost of revenue | $m | [14.7 d](/filings/0001437749-25-036931.md) | [80.4](/filings/0001437749-25-036931.md) | [76.6](/filings/0001437749-25-036931.md) | [79.7](/filings/0001437749-25-036931.md) | [82.1](/filings/0001437749-25-036931.md) | [78.6](/filings/0001437749-26-003200.md) | [80.6](/filings/0001628280-26-032557.md) | [77.5](/filings/0001628280-26-054295.md) | [86.9](/filings/0001437749-25-036931.md) | [84.9](/filings/0001437749-26-003200.md) | [82.8](/filings/0001628280-26-032557.md) | [88.8](/filings/0001628280-26-054295.md) |
| Gross profit | $m | [44.1 d](/filings/0001437749-25-036931.md) | [61.8](/filings/0001437749-25-036931.md) | [59.8](/filings/0001437749-25-036931.md) | [64.6](/filings/0001437749-25-036931.md) | [68.5](/filings/0001437749-25-036931.md) | [68.8](/filings/0001437749-26-003200.md) | [62.8](/filings/0001628280-26-032557.md) | [66.4](/filings/0001628280-26-054295.md) | [72.3](/filings/0001437749-25-036931.md) | [63.7](/filings/0001437749-26-003200.md) | [62.0](/filings/0001628280-26-032557.md) | [72.4](/filings/0001628280-26-054295.md) |
| Research and development | $m | [7.1 d](/filings/0001437749-25-036931.md) | [8.0](/filings/0001437749-25-036931.md) | [8.4](/filings/0001437749-25-036931.md) | [7.6](/filings/0001437749-25-036931.md) | [7.5](/filings/0001437749-25-036931.md) | [7.1](/filings/0001437749-26-003200.md) | [7.6](/filings/0001628280-26-032557.md) | [7.4](/filings/0001628280-26-054295.md) | [8.3](/filings/0001437749-25-036931.md) | [9.2](/filings/0001437749-26-003200.md) | [9.4](/filings/0001628280-26-032557.md) | [8.9](/filings/0001628280-26-054295.md) |
| Selling, general and administrative | $m | [22.4 d](/filings/0001437749-25-036931.md) | [67.9](/filings/0001437749-25-036931.md) | [68.0](/filings/0001437749-25-036931.md) | [62.4](/filings/0001437749-25-036931.md) | [64.7](/filings/0001437749-25-036931.md) | [70.0](/filings/0001437749-26-003200.md) | [69.8](/filings/0001628280-26-032557.md) | [60.1](/filings/0001628280-26-054295.md) | [61.7](/filings/0001437749-25-036931.md) | [60.6](/filings/0001437749-26-003200.md) | [67.9](/filings/0001628280-26-032557.md) | [67.2](/filings/0001628280-26-054295.md) |
| Operating income | $m | [(4.7) d](/filings/0001437749-25-036931.md) | [(14.9)](/filings/0001437749-25-036931.md) | [(24.7)](/filings/0001437749-25-036931.md) | [(7.1)](/filings/0001437749-25-036931.md) | [(4.6)](/filings/0001437749-25-036931.md) | [(8.7)](/filings/0001437749-26-003200.md) | [(18.2)](/filings/0001628280-26-032557.md) | [(1.9)](/filings/0001628280-26-054295.md) | [1.9](/filings/0001437749-25-036931.md) | [(7.2)](/filings/0001437749-26-003200.md) | [(166)](/filings/0001628280-26-032557.md) | [(4.2)](/filings/0001628280-26-054295.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(2.9) d](/filings/0001437749-25-036931.md) | [1.3](/filings/0001437749-25-036931.md) | [1.3](/filings/0001437749-25-036931.md) | [0.6](/filings/0001437749-25-036931.md) | [2.0](/filings/0001437749-25-036931.md) | [3.9](/filings/0001437749-26-003200.md) | [7.2](/filings/0001628280-26-032557.md) | [2.6](/filings/0001628280-26-054295.md) | [(45.4)](/filings/0001437749-25-036931.md) | [3.1](/filings/0001437749-26-003200.md) | [(0.3)](/filings/0001628280-26-032557.md) | [2.4](/filings/0001628280-26-054295.md) |
| Net income | $m | [3.0 d](/filings/0001437749-25-036931.md) | [(14.3)](/filings/0001437749-25-036931.md) | [(137)](/filings/0001437749-25-036931.md) | [(6.6)](/filings/0001437749-25-036931.md) | [(6.6)](/filings/0001437749-25-036931.md) | [(11.0)](/filings/0001437749-26-003200.md) | [(47.7)](/filings/0001628280-26-032557.md) | [(48.0)](/filings/0001628280-26-054295.md) | [50.9](/filings/0001437749-25-036931.md) | [(15.4)](/filings/0001437749-26-003200.md) | [(161)](/filings/0001628280-26-032557.md) | [2.5](/filings/0001628280-26-054295.md) |
| Diluted EPS | $ per share | not reported | [(0.25)](/filings/0001437749-25-036931.md) | [(2.48)](/filings/0001437749-25-036931.md) | [(0.12)](/filings/0001437749-25-036931.md) | [(0.14)](/filings/0001437749-25-036931.md) | [(0.25)](/filings/0001437749-26-003200.md) | [(1.04)](/filings/0001628280-26-032557.md) | [(1.05)](/filings/0001628280-26-054295.md) | [1.11](/filings/0001437749-25-036931.md) | [(0.34)](/filings/0001437749-26-003200.md) | [(3.49)](/filings/0001628280-26-032557.md) | [0.05](/filings/0001628280-26-054295.md) |
| Basic EPS | $ per share | not reported | [(0.25)](/filings/0001437749-25-036931.md) | [(2.48)](/filings/0001437749-25-036931.md) | [(0.12)](/filings/0001437749-25-036931.md) | [(0.14)](/filings/0001437749-25-036931.md) | [(0.25)](/filings/0001437749-26-003200.md) | [(1.04)](/filings/0001628280-26-032557.md) | [(1.05)](/filings/0001628280-26-054295.md) | [1.11](/filings/0001437749-25-036931.md) | [(0.34)](/filings/0001437749-26-003200.md) | [(3.49)](/filings/0001628280-26-032557.md) | [0.05](/filings/0001628280-26-054295.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [649](/filings/0001437749-25-036931.md) | [703](/filings/0001558370-24-000902.md) | [353](/filings/0001558370-24-007628.md) | [337](/filings/0001437749-24-024933.md) | [280](/filings/0001437749-25-036931.md) | [377](/filings/0001437749-25-003325.md) | [254](/filings/0001437749-25-015776.md) | [270](/filings/0001437749-25-025123.md) | [280](/filings/0001628280-26-054295.md) | [337](/filings/0001437749-26-003200.md) | [234](/filings/0001628280-26-032557.md) | [190](/filings/0001628280-26-054295.md) |
| Current assets | $m | [1,419](/filings/0001437749-24-036289.md) | [1,383](/filings/0001558370-24-000902.md) | [1,190](/filings/0001558370-24-007628.md) | [968](/filings/0001437749-24-024933.md) | [833](/filings/0001437749-25-036931.md) | [848](/filings/0001437749-25-036931.md) | [710](/filings/0001437749-25-036931.md) | [678](/filings/0001437749-25-036931.md) | [708](/filings/0001628280-26-054295.md) | [780](/filings/0001437749-26-003200.md) | [727](/filings/0001628280-26-032557.md) | [681](/filings/0001628280-26-054295.md) |
| Total assets | $m | [2,885](/filings/0001437749-25-036931.md) | [2,824](/filings/0001558370-24-000902.md) | [2,563](/filings/0001558370-24-007628.md) | [2,323](/filings/0001437749-24-024933.md) | [2,100](/filings/0001437749-25-036931.md) | [2,043](/filings/0001437749-25-036931.md) | [2,034](/filings/0001437749-25-036931.md) | [2,019](/filings/0001437749-25-036931.md) | [2,060](/filings/0001628280-26-054295.md) | [2,074](/filings/0001437749-26-003200.md) | [1,904](/filings/0001628280-26-032557.md) | [1,876](/filings/0001628280-26-054295.md) |
| Current liabilities | $m | [211](/filings/0001437749-24-036289.md) | [236](/filings/0001558370-24-000902.md) | [203](/filings/0001558370-24-007628.md) | [203](/filings/0001437749-24-024933.md) | [206](/filings/0001437749-25-036931.md) | [203](/filings/0001437749-25-036931.md) | [221](/filings/0001437749-25-036931.md) | [246](/filings/0001437749-25-036931.md) | [238](/filings/0001628280-26-054295.md) | [267](/filings/0001437749-26-003200.md) | [257](/filings/0001628280-26-032557.md) | [273](/filings/0001628280-26-054295.md) |
| Total liabilities | $m | [351](/filings/0001437749-24-036289.md) | [381](/filings/0001558370-24-000902.md) | [341](/filings/0001558370-24-007628.md) | [333](/filings/0001437749-24-024933.md) | [332](/filings/0001437749-25-036931.md) | [323](/filings/0001437749-25-036931.md) | [339](/filings/0001437749-25-036931.md) | [346](/filings/0001437749-25-036931.md) | [333](/filings/0001628280-26-054295.md) | [360](/filings/0001437749-26-003200.md) | [349](/filings/0001628280-26-032557.md) | [366](/filings/0001628280-26-054295.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,534](/filings/0001437749-25-036931.md) | [2,444](/filings/0001437749-25-015776.md) | [2,223](/filings/0001437749-25-025123.md) | [1,990](/filings/0001437749-25-025123.md) | [1,768](/filings/0001628280-26-054295.md) | [1,720](/filings/0001628280-26-032557.md) | [1,695](/filings/0001628280-26-054295.md) | [1,673](/filings/0001628280-26-054295.md) | [1,727](/filings/0001628280-26-054295.md) | [1,715](/filings/0001628280-26-032557.md) | [1,555](/filings/0001628280-26-054295.md) | [1,510](/filings/0001628280-26-054295.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [27.5 d](/filings/0001437749-25-036931.md) | [13.6](/filings/0001437749-25-036931.md) | [8.7 d](/filings/0001437749-25-036931.md) | [9.8 d](/filings/0001437749-25-036931.md) | [17.7 d](/filings/0001437749-25-036931.md) | [29.8](/filings/0001437749-26-003200.md) | [14.4 d](/filings/0001628280-26-032557.md) | [25.8 d](/filings/0001628280-26-054295.md) | [2.2 d](/filings/0001437749-25-036931.md) | [20.8](/filings/0001437749-26-003200.md) | [13.5 d](/filings/0001628280-26-032557.md) | [1.4 d](/filings/0001628280-26-054295.md) |
| Capital expenditure | $m | [10.2 d](/filings/0001437749-25-036931.md) | [11.3](/filings/0001437749-25-036931.md) | [8.3 d](/filings/0001437749-25-015776.md) | [8.5 d](/filings/0001437749-25-025123.md) | [9.4 d](/filings/0001437749-25-036931.md) | [7.8](/filings/0001437749-26-003200.md) | [7.4 d](/filings/0001628280-26-032557.md) | [10.8 d](/filings/0001628280-26-054295.md) | [7.9 d](/filings/0001437749-25-036931.md) | [6.2](/filings/0001437749-26-003200.md) | [7.4 d](/filings/0001628280-26-032557.md) | [6.6 d](/filings/0001628280-26-054295.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [166 d](/filings/0001437749-25-036931.md) | [113](/filings/0001437749-25-003325.md) | [73.9 d](/filings/0001437749-25-015776.md) | [226 d](/filings/0001437749-25-025123.md) | [249 d](/filings/0001437749-25-036931.md) | [0.0](/filings/0001437749-25-003325.md) | [0.0 d](/filings/0001437749-25-015776.md) | [0.0 d](/filings/0001628280-26-054295.md) | [0.0 d](/filings/0001437749-25-036931.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [63.4](/filings/0001437749-24-024933.md) | [56.7](/filings/0001437749-25-036931.md) | [55.4](/filings/0001437749-25-036931.md) | [53.0](/filings/0001437749-25-036931.md) | [48.1](/filings/0001437749-25-036931.md) | [45.6](/filings/0001437749-26-003200.md) | [45.7](/filings/0001628280-26-032557.md) | [45.8](/filings/0001628280-26-054295.md) | [46.0](/filings/0001437749-25-036931.md) | [45.9](/filings/0001437749-26-003200.md) | [46.1](/filings/0001628280-26-032557.md) | [45.3](/filings/0001628280-26-054295.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,808,393 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054295.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.